XTX Topco Ltd Grows Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

XTX Topco Ltd grew its position in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 83.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 20,768 shares of the company’s stock after purchasing an additional 9,468 shares during the quarter. XTX Topco Ltd’s holdings in Y-mAbs Therapeutics were worth $163,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. KLP Kapitalforvaltning AS purchased a new position in shares of Y-mAbs Therapeutics during the 4th quarter valued at $46,000. Wells Fargo & Company MN lifted its position in shares of Y-mAbs Therapeutics by 54.1% during the 4th quarter. Wells Fargo & Company MN now owns 17,458 shares of the company’s stock valued at $137,000 after buying an additional 6,131 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of Y-mAbs Therapeutics by 30.7% during the 4th quarter. SG Americas Securities LLC now owns 17,729 shares of the company’s stock valued at $139,000 after buying an additional 4,163 shares during the last quarter. Principal Financial Group Inc. lifted its position in shares of Y-mAbs Therapeutics by 9.4% during the 4th quarter. Principal Financial Group Inc. now owns 22,197 shares of the company’s stock valued at $174,000 after buying an additional 1,903 shares during the last quarter. Finally, AlphaQuest LLC lifted its position in shares of Y-mAbs Therapeutics by 6,911.6% during the 4th quarter. AlphaQuest LLC now owns 27,135 shares of the company’s stock valued at $212,000 after buying an additional 26,748 shares during the last quarter. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Insider Activity

In related news, insider Thomas Gad sold 10,810 shares of the stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $5.23, for a total transaction of $56,536.30. Following the completion of the sale, the insider now directly owns 202,721 shares in the company, valued at $1,060,230.83. This represents a 5.06 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 22.50% of the company’s stock.

Y-mAbs Therapeutics Trading Up 3.2 %

Shares of Y-mAbs Therapeutics stock opened at $4.23 on Tuesday. The firm has a market capitalization of $191.27 million, a PE ratio of -7.83 and a beta of 0.71. The business’s 50-day moving average price is $4.82 and its 200-day moving average price is $8.03. Y-mAbs Therapeutics, Inc. has a 12 month low of $3.84 and a 12 month high of $17.78.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The firm had revenue of $26.50 million for the quarter, compared to the consensus estimate of $26.70 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same quarter last year, the company posted ($0.02) earnings per share. As a group, analysts predict that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. HC Wainwright dropped their price target on Y-mAbs Therapeutics from $22.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. Bank of America lowered Y-mAbs Therapeutics from a “neutral” rating to an “underperform” rating and set a $3.00 price objective on the stock. in a research note on Tuesday, April 22nd. Wedbush reiterated an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. Morgan Stanley decreased their price objective on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a research note on Wednesday, March 5th. Finally, Truist Financial decreased their price objective on Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, March 5th. Two investment analysts have rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $17.40.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.